Last updated: March 30, 2026
What is the Drug NDC 69315-0226?
NDC 69315-0226 refers to a specific formulary drug. Based on available databases, it is identified as Sage (fluoxetine hydrochloride) 20 mg capsule. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) prescribed primarily for depression, obsessive-compulsive disorder, and other mood disorders.
Market Context
Competition Landscape
The fluoxetine market is characterized by:
- Several FDA-approved brands: Prozac (Eli Lilly), Sarafem (Sage), and generic versions.
- A high prevalence of depression in US adults—approximately 8.4% as per National Institute of Mental Health (NIMH) [1].
- An estimated 45 million prescriptions annually, with generic drugs accounting for around 75% of sales [2].
Regulatory Status
- Approved since 1987, fluoxetine is considered a mature, off-patent drug.
- The patent expiry for Prozac occurred in 2001.
- Multiple generic manufacturers sell 20 mg fluoxetine capsules, reducing market prices.
Distribution Channels
- Retail pharmacies account for 70% of prescriptions.
- Institutional providers and mail-order pharmacies comprise the remainder.
Prescriber and Payer Dynamics
- Prescribers favor SSRIs due to efficacy and safety profile.
- Insurance coverage is widespread, with formulary inclusion influencing access and price.
Current Pricing Landscape
Market Prices
| Source |
Average Price per 30-Count Bottle |
Notes |
| GoodRx |
$10–$15 |
Price for brand/generic on discount platforms |
| Medicare Part D |
$5–$8 |
Co-payments vary by plan |
| Wholesale Acquisition Cost (WAC) |
~$2–$3 |
Estimated generic WAC |
Price Trends
- Generic fluoxetine prices have declined sharply since patent expiration.
- The average retail price has stabilized around $0.05–$0.10 per capsule.
- Bulk purchasing and insurance-negotiated prices often result in lower out-of-pocket costs.
Key Factors Affecting Price
- Increased generic competition has driven prices down.
- State Medicaid programs and PBMs leverage formulary negotiations to reduce costs.
- No significant supply constraints or shortages.
Forecasting Price Trends
Short-Term (Next 12 Months)
Prices will likely remain stable or decline slightly as:
- Additional generic manufacturers increase production.
- Market saturation intensifies, reducing margins.
- Payer formularies favor lowest-cost generics.
Projected Price Range: $0.04–$0.08 per capsule.
Medium to Long-Term (1–3 Years)
Given the mature status of the market:
- Prices are unlikely to decrease significantly further.
- New formulations or delivery methods are improbable.
- Patent-related activities are unlikely to influence prices.
Projected Price Range: $0.04–$0.07 per capsule with minimal fluctuations.
Potential Market Drivers and Risks
-
Market Drivers:
- Expansion of indications or new formulations.
- Increased awareness of mental health treatment.
- Cost-containment measures by insurers.
-
Market Risks:
- Entry of competing generics driving prices down.
- Changes in prescribing guidelines or insurance formularies.
- Supply chain disruptions—currently not observed.
Investment and R&D Implications
- The low-cost, saturated market limits revenue upside for new entrants.
- Investment is better directed at novel therapies or formulations with patent protection.
- Opportunities exist in combination therapies or enhanced delivery systems.
Key Takeaways
- NDC 69315-0226 (fluoxetine 20 mg) is part of a mature, highly competitive, and low-price market.
- Prices are driven predominantly by generic competition, leading to stable, low retail costs.
- Future price movements are expected to be minimal, barring market disruptions.
- Market growth is primarily driven by demand for mental health therapies, not price increases.
FAQs
Q1: Are there any expected patent expirations or exclusivity periods for fluoxetine?
No, fluoxetine’s patent expired in 2001; the market is highly genericized.
Q2: Can prices for fluoxetine increase significantly in the future?
Unlikely, due to saturation from multiple generic manufacturers and aggressive price competition.
Q3: Are there emerging formulations that could impact the market?
No significant new formulations are currently under development for fluoxetine; focus remains on generics.
Q4: How does insurance coverage influence market prices?
Insurance negotiations and formulary placements lower out-of-pocket costs for patients and can influence retail prices.
Q5: What is the key market restriction for new competitors?
Market saturation and established generic suppliers limit potential profit margins.
References
[1] National Institute of Mental Health. (2021). Major Depression.
[2] IQVIA. (2022). The Impact of Patent Expirations on the US Generic Market.
